♥ HF Guideline NavigatorESC 2026

1

1 Preamble

Pages 7–9 · open in PDF

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 7 · PDF

i.v. IABP ICA ICD ID INTERMACS KCCQ

LBBB LGE LV LVAD LVEF MCS MI MR MRA MR-proANP NT-proBNP NYHA OSA PaO2 PCI PVC QoL RCT RHC RV SCAI SCD SDB SGLT2 SGLT2-I SHARC S-ICD SpO2 T2DM TAVI TEER TR TSAT TTR UACR uNa+ WHF WHO

For acronyms of studies and trials, see Supplementary data online, Table S1.

1. Preamble Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. ESC Guidelines are intended for use by health professionals but do not override their individual responsibility to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with the patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and to respect the ethical rules of their profession. ESC Guidelines represent the official position of the ESC on a given topic. Guideline topics are selected for updating after annual expert review of new evidence conducted by the ESC Clinical Practice Guidelines (CPG) Committee. ESC Policies and Procedures for formulating and issuing ESC Guidelines can be found on the ESC website (https://www.escardio.org/ Guidelines/Clinical-Practice-Guidelines/Guidelines-development/ Writing-ESC-Guidelines). This guideline updates and replaces the previous version from 2021. This Task Force was selected by the ESC to include professionals involved with the medical care of patients with this pathology and to include patient representatives and methodologists. The selection procedure included an open call for authors and aimed to include members from across the entire ESC region and from relevant ESC Subspecialty Communities. Consideration was given to diversity and inclusion. Guidelines Task Forces perform a critical review and evaluation of the published literature on diagnostic and therapeutic approaches including assessment of the risk–benefit ratio. Recommendations are based on major randomized trials and relevant systematic reviews and meta-analyses, when available. Systematic literature searches are conducted in cases of controversy or uncertainty to ensure that all key studies are considered. For recommendations related to diagnosis and prognosis, additional types of evidence are included, such as diagnostic accuracy studies and studies focused on the development and validation of prognostic models. The strength of each recommendation and the level of evidence supporting it are weighed and scored according to predefined criteria. The criteria for grading the strength of recommendations are described in Table 1. A new system for grading levels of evidence for ESC Guidelines has been published1,2 and utilized for the first time in 2026 ESC Guidelines. For therapy and prevention, the framework includes consideration of study type and the number of studies supporting a recommendation, as well as whether a study is adequately powered, shows substantial evidence against the play of chance, and is free of major sources of bias. This is described in Table 2. A separate grading system has also been developed for diagnostic tests and prediction models, which is described in Table 3.

Intravenous Intra-aortic balloon pump Invasive coronary angiography Implantable cardioverter-defibrillator Iron deficiency Interagency Registry for Mechanically Assisted Circulatory Support Kansas City Cardiomyopathy Questionnaire Kidney Disease: Improving Global Outcomes Left bundle branch block Late gadolinium enhancement Left ventricular Left ventricular assist device Left ventricular ejection fraction Mechanical circulatory support Myocardial infarction Mitral regurgitation Mineralocorticoid receptor antagonist Mid-regional pro-atrial natriuretic peptide N-terminal pro-B-type natriuretic peptide New York Heart Association Obstructive sleep apnoea Partial pressure of oxygen Percutaneous coronary intervention Premature ventricular contraction Quality of life Randomized controlled trial Right heart catheterization Right ventricular Society for Cardiovascular Angiography and Interventions Sudden cardiac death Sleep-disordered breathing Sodium–glucose co-transporter 2 Sodium–glucose co-transporter 2 inhibitor Shock Academic Research Consortium Subcutaneous implantable cardioverter-defibrillator Oxygen saturation Type 2 diabetes mellitus Transcatheter aortic valve implantation Transcatheter edge-to-edge repair Tricuspid regurgitation Transferrin saturation Transthyretin Urine albumin-to-creatinine ratio Urinary sodium Worsening heart failure World Health Organization

Page 8 · PDF

Classes of recommendations

Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.

“is recommended” or “is indicated”

Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.

Weight of evidence/opinion is in favour of usefulness/efficacy.

Usefulness/efficacy is less well established by evidence/opinion.

Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.

entirely from the ESC with no involvement of the healthcare industry. The CPG Committee supervises and coordinates the preparation of new guidelines and approves their publication. In addition to review by the CPG Committee, ESC Guidelines undergo multiple rounds of double-blind peer review on a dedicated online review platform. The review is conducted by a panel of 70 or more topic experts including members from ESC National Cardiac Societies and from relevant ESC Subspecialty Communities. Reviewers critically assess and comment on the content of the Guidelines and grade their comments as major and minor. Guideline Task Forces consider all review comments and are required to respond on the online platform to all those classified as major. The review comments inform revisions after each round. After the final review round and the second Task Force vote on all recommendations, the Task Force and the CPG Committee members approve the final document for publication in the European Heart Journal. Unless otherwise stated, ESC Guidelines content refers to sex, understood as the biological condition of being male or female, defined by genes, hormones, and sexual organs. Off-label use of medication may be presented in this guideline if a sufficient level of evidence shows that it can be considered medically appropriate for a given condition. However, decisions on off-label use must be made by the responsible health professional giving special consideration to ethical rules concerning healthcare, the specific situation of the patient, patient consent, and country-specific health regulation.

Patient-Reported Outcome Measures (PROMs) and Patient-Reported Experience Measures (PREMs) are also evaluated when available as the basis for recommendations and/or discussion in these guidelines. Evidence tables summarizing key information from relevant studies are generated to facilitate the formulation of recommendations, to enhance comprehension of recommendations after publication, and to reinforce transparency in the guidelines development process. The tables are published in their own section of ESC Guidelines and reference specific recommendation tables. After an iterative process of deliberations, a first Task Force vote on all recommendations is conducted prior to the initiation of rounds of review. A second Task Force vote on all recommendations is conducted after the final round of review and revision. For each vote, the Task Force follows ESC voting procedures: to achieve quorum, at least two-thirds of the Task Force must vote agree or disagree, and to be approved all recommendations require at least 75% of votes in favour, excluding abstentions. Restrictions on voting and on participation in task force deliberations are applied as needed based on declarations of interest. The writing and reviewing panels provide declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest are reviewed according to the ESC declaration of interest rules, which can be found on the ESC website (http://www.escardio.org/doi) and are compiled in a report published in a supplementary document with the guidelines. Funding for the development of ESC Guidelines is derived

Page 9 · PDF

Levels of evidence—therapy and prevention

Definition Conclusive evidence, usually from at least two adequately powered randomized controlled trialsa free of major bias, with substantial evidence against the play of chance when combined in a meta-analysis (e.g., P <0.005 for superiority).b

Suggestive evidence from at least one adequately powered randomized controlled trial free of major bias, or a meta-analysis of such randomized controlled trials, with some evidence against the play of chance (e.g., P <0.05 for superiority).c

Limited evidence from at least two adequately powered non-randomized studies with careful control of major sources of bias and substantial evidence against the play of chance (e.g., P <0.005 for superiority),b or from a meta-analysis of small, underpowered randomized controlled trials with some evidence against the play of chance (e.g., P <0.05 for superiority).c

Preliminary evidence from non-randomized studies without careful control of major sources of bias, a single small, underpowered randomized controlled trial, or expert consensus.

Exceptionally, level of evidence A can be considered if (1) there is a single very large randomized controlled trial that provides convincing evidence across a wide range of patients that is already widely accepted by most practitioners, or (2) the effects of the intervention are clinically obvious; in either case, over 90% of voting guideline task force members need to agree with level of evidence A. b Studies do not need to individually show substantial evidence against the play of chance (e.g. a P-value of <.005 for superiority) if a meta-analysis of these studies provides such evidence. c Studies do not need to individually show some evidence against the play of chance (e.g. a P-value of <.05 for superiority) if a meta-analysis of these studies provides such evidence.

Prediction model (including diagnostic and prognostic models)

Conclusive evidence of adequate diagnostic ability from at least two high-quality studies

Conclusive evidence of adequate predictive ability from at least one high-quality derivation study, and two or more external validation studies of at least moderate quality.

Suggestive evidence of adequate diagnostic ability from a single high-quality or at least two moderate-quality studies.

Suggestive evidence of adequate predictive ability from one or more derivation and one or more external validation studies of at least moderate quality.

Preliminary evidence of adequate diagnostic ability from a single moderate-quality study, any number of low-quality studies, or expert consensus.

Preliminary evidence of adequate predictive ability from a derivation study of at least moderate quality, but with external validation absent or in a low-quality study, or a derivation study of low quality (irrespective of external validation).

Table 3 Levels of evidence—diagnostic tests and prediction models

2. Introduction In these guidelines, we have redefined the classification of heart failure (HF) compared with the definition used in the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure,3 and provided a simple definition that we believe will translate into everyday clinical practice. As early detection of HF is increasingly important, we have, in alignment with the

2022 AHA/ACC/HFSA Guideline for the management of heart failure,4 also included risk factors and early signs of HF into the staging of HF. An updated classification for the treatment of HF has also been added, which emphasizes foundational and additional medical therapies, as well as interventional therapies. Figure 1 provides an overview of current management recommendations for HF. Since the publication of the 2021 ESC Guidelines for the diagnosis and treatment of acute and